If you or a loved one is living with vitiligo, you’re likely familiar with the challenges of finding effective, safe treatment options. Among the most widely used therapies, 308-nm phototherapy has emerged as a gold standard for targeting depigmented skin lesions. But with two primary devices—308-nm light-emitting diode (LED) and 308-nm monochromatic excimer lamp (MEL)—many patients wonder: Which one is right for me? Let’s dive into the latest clinical research to break down efficacy, safety, and practical considerations for both adults and children.

How 308-nm Phototherapy Works for Vitiligo

First, a quick primer: 308-nm phototherapy uses targeted ultraviolet light to stimulate melanocyte regeneration—the cells responsible for skin pigment. Unlike broader UVB treatments, 308-nm devices deliver a concentrated, precise wavelength that minimizes exposure to healthy skin, making them ideal for localized lesions, including on the face and in pediatric cases. Both LED and MEL technologies leverage this wavelength, but their delivery methods (and real-world applications) differ—something recent studies have shed critical light on.

Efficacy Showdown: LED vs. Excimer Lamp

The core question for many patients is: Do these devices perform equally well? The answer depends on your specific case—including age, lesion location, and treatment setting.

For Adult Facial Vitiligo: Equally Effective

A 2025 randomized controlled trial published in Arch Dermatol Res compared 308-nm LED and 308-nm MEL in 119 adults with stable non-segmental facial vitiligo. Over two months of treatment:

• After 1 month: LED achieved an 11.84% efficacy rate (repigmentation improvement) vs. 7.24% for MEL.
• After 2 months: LED’s efficacy rose to 42.1% vs. 39.12% for MEL.
• The average repigmentation grade (a measure of skin color restoration) was 2.38 for LED and 2.19 for MEL.

Crucially, the differences were statistically insignificant (P = .349 at 1 month; P = .416 at 2 months), confirming that both devices are equally effective for treating facial vitiligo in adults. For patients prioritizing results over device type, this means flexibility—whether choosing a clinic-based MEL or a more portable LED.

For Pediatric Vitiligo: Setting Matters Most

A 2025 retrospective study in Photodermatol Photoimmunol Photomed focused on 75 children with vitiligo, comparing home-based 308-nm LED to hospital-based 308-nm MEL. The findings revealed a key caveat:

• After 48 sessions: Hospital-based MEL had a far higher efficacy rate (79.5%) than home-based LED (38.9%, p < 0.001).
• However, when cumulative light doses were matched, efficacy became nearly identical (p > 0.05).

The gap stemmed from dose adjustments: home-based LED users often received lower, more cautious doses without direct clinical supervision. For kids, this means hospital-based MEL may deliver better results when adherence to optimal dosing is a concern—but home-based LED remains a viable option with proper guidance. The study also noted that shorter disease duration and stable vitiligo correlated with better outcomes for both devices, emphasizing the importance of early intervention.

Safety: No Increased Skin Cancer Risk—And Manageable Side Effects

Safety is a top priority for any long-term vitiligo treatment, and 308-nm phototherapy excels here.

No Link to Skin Cancer

A 2019 population-based retrospective cohort study in Pigment Cell Melanoma Res analyzed 5,052 vitiligo patients in Korea who received 308-nm excimer laser (a close cousin to MEL) treatments. Even for patients who underwent 100+ sessions:

• No significant increase in risk of actinic keratosis (premalignant lesions), non-melanoma skin cancer, or melanoma.
• The study concluded that 308-nm excimer therapy is a safe long-term option for localized vitiligo, with no elevated cancer risks.

Side Effects: Mild and Comparable (With Exceptions for Home Use)

In the adult facial vitiligo trial, side effect rates were similar between LED and MEL (P = .332), with most being mild (e.g., redness, mild irritation)—typical of targeted phototherapy.

For pediatric patients, however, home-based LED had a higher rate of adverse events (63.9% vs. 30.8% for hospital-based MEL, p = 0.029). Again, this was linked to dosing inconsistencies and lack of in-person monitoring, not the device itself. The solution? Better patient education and digital tools (like AI-driven dose trackers) to enhance safety for home therapy—an area researchers are actively exploring.

Choosing the Right 308-nm Device: Practical Tips

Based on the research, here’s how to decide between LED and MEL:

• Adults with facial vitiligo: Either device works—opt for LED if portability or home use is important, or MEL if you prefer clinic-based treatment.
• Children: Prioritize hospital-based MEL for higher efficacy, unless home therapy is necessary (e.g., due to distance or scheduling). If using home LED, work closely with your dermatologist to adjust doses and monitor progress.
• All patients: Seek early treatment (shorter disease duration = better results) and ensure consistent, optimal dosing—whether supervised in a clinic or guided at home.

The Bottom Line

308-nm LED and MEL are both safe, effective treatments for vitiligo, with outcomes largely depending on age, treatment setting, and dosing adherence. For adults with facial lesions, the choice comes down to convenience; for kids, clinic-based MEL may offer better results, but home LED is a solid alternative with proper support.

As research continues to refine these therapies—including digital tools to improve home treatment safety—vitiligo patients have more reliable options than ever.